About

We are proud to serve a purpose beyond ourselves.

Our story

Better outcomes for patients with unmet needs

The Abacus Medicine Group was founded in 2004 to improve access to critical medicines throughout Europe, driven by the vision of supporting better healthcare and outcomes for patients with unmet medical needs.

Abacus Medicine Pharma Services (AMPS) is the pharma services division of the Abacus Medicine Group and launched in 2014. We provide bespoke, end-to-end commercialisation solutions for global innovators who want to successfully launch their products in the European Union and United Kingdom.

The combination of AMPS’ industry experience with the market-leading operational capabilities of the Group provides our clients with a trusted framework for launching their innovative assets and achieving their commercial objectives.

Milestones

2014
Formed and launched as Aposave, a separate company affiliated with the Abacus Medicine Group
2016
Establishment of Asia-Pacific subsidiary in Hong Kong and North American subsidiary in New York City
2022
Rebranded to become Abacus Medicine Pharma Services, embracing the Group’s identity; combined revenue of the Group’s business units surpasses €1 billion
Our vision and mission

Sharing a common purpose

Abacus Medicine Pharma Services strives to create universal access to rare diseases medicines through impactful commercialisation solutions.

We aim:

  • to empower our partners with bold and innovative commercialisation solutions.
  • to strengthen key stakeholder relationships through transparent, engaging, and trusting collaboration.
  • to advance patient well-being by ensuring swift and caring access to transformative treatments.

Leadership

Our experienced management team has extensive experience working for and with global pharmaceutical and biotech firms serving the rare disease community.

Managing Director

Flemming Wagner

Mr. Wagner is CEO and majority shareholder of Abacus Medicine. Prior to founding Abacus Medicine A/S in 2004, Mr. Wagner was the CEO of RAMCON A/S, a company focused on analytical and diagnostic equipment for hospitals and pharmaceutical industries.

VP Medical & Technical SERVICES

Maxine Hamilton

Prior to joining AMPS in 2019, Maxine was Idis’ SVP of Managed Access Programs in Princeton, NJ and the Managing Director of Managed Access following its acquisition by Clinigen.

VP Product Strategy & Market Access

Marco Wulff

Prior to joining AMPS in 2020, Marco worked across the Abacus Medicine Group business heading up strategy and transformation projects.

Director, Analysis & Insights

Brett Wynn

Brett worked for the UK affiliate for Alliance Healthcare and Alcura, part of the former Walgreens Boots Alliance group, before joining AMPS in 2019.

VP Strategic Partnerships

Mark Ostle

Mark has 15 years’ experience within the Walgreens Boots Alliance group and is the former Head of Commercial at Alcura. He joined AMPS in 2019.

VP Sales & Operations

Alexander Iversen

Prior to joining AMPS in 2023, Alexander was Head of Corporate Strategy at Abacus Medicine Group, with deep experience within product management.